Volume | 4,513,134 |
|
|||||
News | - | ||||||
Day High | 126.3843 | Low High |
|||||
Day Low | 122.01 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Moderna Inc | MRNA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
125.06 | 122.01 | 126.3843 | 125.00 | 125.59 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
71,479 | 4,513,134 | $ 124.14 | $ 560,253,414 | - | 62.55 - 142.79 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:59:12 | 10 | $ 125.36 | USD |
Moderna (MRNA) Options Flow Summary
Moderna Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
47.76B | 382.07M | - | 6.85B | -4.71B | -12.34 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Moderna News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MRNA Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 106.18 | 128.81 | 105.25 | 118.08 | 4,774,627 | 19.18 | 18.06% |
1 Month | 101.75 | 128.81 | 99.30 | 110.51 | 3,444,043 | 23.61 | 23.20% |
3 Months | 93.36 | 128.81 | 84.06 | 102.75 | 3,967,276 | 32.00 | 34.28% |
6 Months | 73.02 | 128.81 | 67.62 | 96.24 | 4,360,854 | 52.34 | 71.68% |
1 Year | 130.66 | 142.79 | 62.55 | 102.56 | 4,069,072 | -5.30 | -4.06% |
3 Years | 183.49 | 497.17 | 62.55 | 219.50 | 6,946,956 | -58.13 | -31.68% |
5 Years | 28.89 | 497.17 | 11.54 | 147.52 | 8,810,810 | 96.47 | 333.92% |
Moderna Description
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 44 mRNA development programs as of early 2022, with 25 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases. |